THE US Food and Drug
administration has approved
Janssen Pharmaceuticals’ Invokana
(canagliflozin) for the treatment of
adults with type 2 diabetes.
Invokana is the first in a new
class of medications called sodium
glucose co-transporter 2 (SGLT2)
inhibitors to be approved in the US.
It’s an oral once-daily medication
which offers improved glycaemic
control while also showing reduced
body weight and systolic blood
pressure in clinical trials.
Janssen said it would partner
with other J&J companies focused
on diabetes (such as LifeScan
and Animas) to bring Invokana
to healthcare professionals, and
would also offer a dedicated
“Invokana CarePath” program to
patients, providing “important
support and information regarding
affordable access, adherence and
education, thereby helping patients
to start and appropriately manage
their disease and therapy over
time,” the company said.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Apr 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.